MedTrace Logo

Effect of Denileukin Diftitox on Immune System in CTCL Patients

NCT00254332 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-03-25

No results posted yet for this study

Summary

This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma.

Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

Conditions

  • Cutaneous T-cell Lymphoma
  • Sezary Syndrome
  • Mycosis Fungoides

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Larisa J. Geskin, M.D. · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00254332 on ClinicalTrials.gov